The Unlikely Renaissance Of Gene Therapy
This article was originally published in Start Up
After a decade of doubts, fears, and scares, advances in gene therapy have brought one drug close to approval, and a few venture-backed start-ups are gaining momentum. Is it enough to persuade more VCs to jump in?
You may also be interested in...
VC Roundup: 2Q Financings Fall As Per-Company Averages Rise
Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
Bluebird Bio Raises $60M Series D Round To Treat Rare Diseases
The gene therapy start-up taps diversified public and private investors, as well as strategic backer Shire, for one of the year’s biggest rounds of private capital funding for a biotech thus far.
EU's CHMP Clears Europe's First Gene Therapy, UniQure's Glybera
After three previous negative votes, the Netherlands biotech uniQure gains the first positive opinion from the Committee for Medicinal Products for Human Use for a gene therapy in Europe. Glybera is used to treat the ultra-rare condition lipoprotein lipase deficiency.